Improving compliance with Helicobacter pylori eradication therapy: When and how?

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 5, 2009, Pages 273-279

  O'connor, John P Anthony ^a   Taneike, Ikue ^a   O'morain, Colm ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Compliance; Gastric cancer; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN;

DOCTOR PATIENT RELATION; ERADICATION THERAPY; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PATIENT COMPLIANCE; PATIENT INFORMATION; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

EID: 77953445238     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09337342     Document Type: Review

References (39)

1. Al-Eidan, F.A., McElnay, J.C., Scott, M.G. and McConnell, J.B. ( 2002) Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol 53: 163-171.
2. Borody, T.J., Pang, G., Wettstein, A.R., Cloancy, R., Herdman, K., Surace, R. et al. (2006) Efficacy and Safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 23: 481-488.
3. Calvet, X., García, N., López, T., Gisbert, J.P., Gené, E. and Roque, M. ( 2000) A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 14: 603-609.
4. Chey, W.D. and Wong, B.C. ( 2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102: 1808-1825.
5. Coelho, L.G., Moretzsohn, L.D., Vieira, W.L., Gallo, M.A., Passos, M.C., Cindr, J.M. et al. (2005) New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 21: 783-787.
6. Cremonini, F., Di Caro, S., Covino, M., Armuzzi, A., Gabrielli, M., Santarelli, L. et al. (2002) Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97: 2744-2749.
7. de Boer, W.A., Thys, J.C., Borody, T.J., Graham, D.Y., O'Morain, C.A. and Tytgat, G.N. ( 1996) Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 8: 641-643.
8. Dickson, M. and Plauschinat, C.A. ( 2008) Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 8: 45-50.
9. Düsing, R., Lottermoser, K. and Mengden, T. ( 2001) Compliance with drug therapy-new answers to an old question. Nephrol Dial Transplant 16: 1317-1321.
10. Fuccio, L., Minardi, M.E., Zagari, R.M., Grilli, D., Magrin, N. and Bazzoli, F. ( 2007) Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 147: 553-562.
11. Graham, D.Y., Lew, G.M., Malaty, H.M., Evans, D.G., Evans Jr, D.J. and Klein, P.D. ( 1992) Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102: 493-496.
12. Henry, A. and Batey, R.G. ( 1999) Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP study. Am J Gastroenterol 94: 811-815.
13. Howden, C.W., Blume, S.W. and de Lissovoy, G. ( 2007) Practice patterns for managing Helicobacter pylori infection and upper gastrointestinal symptoms. Am J Manag Care 13: 37-44.
14. Inoue, M., Iwasaki, M., Otani, T., Sasazuki, S. and Tsugane, S. ( 2006) Public awareness of risk factors for cancer among the Japanese general population: A population-based survey. BMC Public Health 6: 2.
15. International Agency for Research on Cancer. (1994) Schistosomes, liver flukes and Helicobacter pylori.
16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61: 1-241.
17. Jafri, N.S., Hornung, C.A. and Howden, C.W. ( 2008) Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 148: 923-931.
18. Kadayifci, A., Buyukhatipoglu, H., Cemil Savas, M. and Simsek, I. ( 2006) Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 28: 1960-1966.
19. Kearney, D.J. and Brousal, A. ( 2000) Treatment of Helicobacter pylori infection in clinical practice in the United States. Dig Dis Sci 45: 265-271.
20. Kim, M.N., Kim, N., Lee, S.H., Park, Y.S., Hwang, J.H., Kim, J.W. et al. (2008) The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 13: 261-268.
21. Lam, S.K. and Talley, N.J. ( 1998) Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13: 1-12.
22. Lee, M., Kemp, J.A., Canning, A., Egan, C., Tataronis, G. and Farraye, F.A. ( 1999) A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 159: 2312-2316.
23. Lind, T., van Zanten, S. Veldhuyzen, Unge, P., Spiller, R., Bayerdorffer, E., O'Moráin, C. et al. (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1: 138-144.
24. Lutfey, K.E. and Wishner, W.J. ( 1999) Beyond ‘compliance’ is ‘adherence’. Improving the prospect of diabetes care. Diabetes Care 22: 635-639.
25. Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D. et al. (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772-781.
26. Mateo, J.F., Gil-Guillén, V.F., Mateo, E., Orozco, D., Carbayo, J.A. and Merino, J. ( 2006) Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract 60: 422-428.
27. Megraud, F. ( 2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 1374-1384.
28. Misiewicz, J.J., Harris, A.W., Bardham, K.D., Levi, S., O'Moráin, C.A., Cooper, B.T. et al. (1997) One week triple therapy for helicobacter pylori: a multocentre comparative study. Gut 41: 735-739.
29. Niv, Y. and Abuksis, G. ( 2003) Survey of the opinions, knowledge and practices of surgeons and internists regarding Helicobacter pylori test-and-treat policy. J Clin Gastroenterol 36: 139-143.
30. Pan, F., Chernew, M.E. and Fendrick, A.M. ( 2008) Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 23: 611-614.
31. Rispo, A., Di Girolamo, E., Cozzolino, A., Bozzi, R., Morante, A. and Pasquale, L. ( 2007) Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter 12: 364-365.
32. Rokkas, T., Sechopoulos, P., Robotis, I., Margantis, G. and Pistiolas, D. ( 2009) Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by the Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 104: 21-25.
33. Rupnow, M.F.T., Owens, D., Shachter, R. and Parsonnet, J. ( 1999) Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 4: 272-280.
34. Seppälä, K., Kosunen, T.U., Veijola, L., Sipponen, P., Arkkila, P.E., Rautelin, H. et al. (2008) Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects. Scand J Gastroenterol 43: 1149-1150.
35. Sharma, V.K., Bailey, D.M., Raufman, J.P., Elraie, K., Metz, D.C., Go, M.F. et al. (2000) A survey of internal medicine residents’ knowledge about Helicobacter pylori infection. Am J Gastroenterol 95: 1914-1919.
36. Spahr, L., Rubbia-Brandt, L., Marinescu, O., Armenian, B. and Hadengue, A. ( 2001) Acute fatal hepatitis related to levofloxacin. J Hepatol 35: 308-309.
37. Stratton, K.R., Durch, J.S. and Lawrence, R.S. ( 2000) Vaccines for the 21st century. A tool for decision making, The National Academies Press: Washington.
38. van der Linden, P.D., Sturkenboom, M.C., Herings, R.M., Leufkens, H.G. and Stricker, B.H. (2002) Fluoroquinolones and risk of Achilles tendon disorders. BMJ 324: 1306-1307.
39. Zagari, R.M., Bianchi-Porro, G., Fiocca, R., Gasbarrini, G., Roda, E. and Bazzoli, F. ( 2007) Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 56: 475-479.